Quantifying the burden of disease in patients with Lennox Gastaut syndrome
| Autor: | Teresa Greco, Silvia Faini, Christian Senft, Maxine Dibué, Marcel A. Kamp, Jochem K H Spoor |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Neurophysiology and neuropsychology
Burden of disease Pediatrics medicine.medical_specialty LGS Lennon-Gastaut Syndrome Drug-resistant epilepsy urologic and male genital diseases Article Behavioral Neuroscience ASM antiseizure medication VNS medicine In patient RC346-429 Seizure types Epileptic encephalopathy business.industry QP351-495 medicine.disease Lennox–Gastaut Syndrome VNS vagus nerve stimulation Neurology Neurology. Diseases of the nervous system Neurology (clinical) business Vagus nerve stimulation Lennox–Gastaut syndrome |
| Zdroj: | Epilepsy & Behavior Reports Epilepsy & Behavior Reports, Vol 16, Iss, Pp 100508-(2021) |
| ISSN: | 2589-9864 |
| Popis: | Highlights • Analysis of 705 and 1410 DRE patients with and without LGS later treated with VNS. • 40% of LGS-DRE patients had polypharmacy with 3 antiseizure medications. • 42% of e non-LGS-DRE patients had polypharmacy with 2 antiseizure medications. • Monthly seizure counts were similar within the two groups regardless of how many ASMs were being taken. • Median total monthly seizure frequency in the LGS-DRE group was more than double. • Bilateral tonic clonic seizure were the main contributor to the higher seizure frequency. Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy but there is limited literature characterizing the disease burden despite this being crucial for disease management strategies, and for designing and interpreting clinical trials. We searched the Vagus Nerve Stimulation (VNS) Therapy Patient Outcome Registry including over 7000 patients with drug‑resistant epilepsy (DRE). Propensity Score Matching (PSM) matched LGS-DRE patients and non-LGS-DRE patients and frequencies of individual seizure types were assessed. The PSM population included 705 and 1410 DRE patients with and without LGS. 40% of the LGS-DRE group had polypharmacy with 3 antiseizure medications (ASM) while 42% in non-LGS-DRE had polypharmacy with 2 ASMs. Median total monthly seizure frequency was over double in the LGS group: 90 (IQR, 28–312) versus 40 (IQR, 10–150); p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|